Related Experiment Video
Updated: Feb 19, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
6.0K
Coronary sinus Reducer non-responders: insights and perspectives
Luca Baldetti1, Antonio Colombo, Shmuel Banai
1Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Summary
A new method predicts patient response to Coronary Sinus (CS) Reducer therapy for refractory angina by measuring pressure differences. This helps identify patients likely to benefit, avoiding ineffective treatments.
Area of Science:
- Cardiovascular Interventions
- Interventional Cardiology
- Medical Device Technology
Background:
- Coronary Sinus (CS) Reducer is indicated for refractory angina in patients unsuitable for revascularization.
- A significant percentage of patients do not respond to CS Reducer therapy.
- Alternative coronary venous drainage systems are hypothesized to influence treatment response.
Observation:
- A method was developed to measure differential pressure between right atrial pressure and CS systolic pressure during balloon occlusion.
- High differential pressure indicates effective CS Reducer interference with coronary venous return.
- Low differential pressure suggests developed accessory venous drainage, potentially limiting Reducer efficacy.
Findings:
- The differential pressure measurement can predict responsiveness to CS Reducer implantation.
- Patients with high differential pressure are expected to benefit most from the Reducer.
- Patients with low differential pressure may experience minimal benefits due to alternative venous drainage.
Implications:
- This simple peri-procedural method aids in selecting appropriate candidates for CS Reducer therapy.
- It helps avoid unnecessary procedures and associated risks for non-responders.
- Understanding CS hemodynamics offers insights into the pathophysiology and effects of Reducer treatment.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
309
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
309
01:27Coronary Artery Disease V: Interprofessional Care
315
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
315
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
01:26Coronary Artery Disease IV: Preventive Measures
741
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741
01:26Mitral Stenosis III: Medical Management
328
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
328
01:30Heart Failure V: Medical Management
381
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
381